These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
620 related articles for article (PubMed ID: 20924102)
21. Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice. Suffner J; Hochweller K; Kühnle MC; Li X; Kroczek RA; Garbi N; Hämmerling GJ J Immunol; 2010 Feb; 184(4):1810-20. PubMed ID: 20083650 [TBL] [Abstract][Full Text] [Related]
22. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination. Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789 [TBL] [Abstract][Full Text] [Related]
23. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Saha A; Chatterjee SK Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858 [TBL] [Abstract][Full Text] [Related]
24. Tolerogenic dendritic cells induce CD4+CD25hiFoxp3+ regulatory T cell differentiation from CD4+CD25-/loFoxp3- effector T cells. Huang H; Dawicki W; Zhang X; Town J; Gordon JR J Immunol; 2010 Nov; 185(9):5003-10. PubMed ID: 20870943 [TBL] [Abstract][Full Text] [Related]
25. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
27. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581. Banham AH; Pulford K Expert Opin Ther Pat; 2009 Jul; 19(7):1023-8. PubMed ID: 19456276 [TBL] [Abstract][Full Text] [Related]
29. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208 [TBL] [Abstract][Full Text] [Related]
30. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Rech AJ; Vonderheide RH Ann N Y Acad Sci; 2009 Sep; 1174():99-106. PubMed ID: 19769742 [TBL] [Abstract][Full Text] [Related]
31. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice. Qu Y; Zhang B; Zhao L; Liu G; Ma H; Rao E; Zeng C; Zhao Y Transpl Immunol; 2007 Apr; 17(3):153-61. PubMed ID: 17331841 [TBL] [Abstract][Full Text] [Related]
32. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses. Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495 [TBL] [Abstract][Full Text] [Related]
33. [Effects of excreted/secreted antigens of Toxoplasma gondii on CD4+ CD25+ Foxp3+ T cells and NK cells of melanoma-bearing mice]. Jiao YM; Zhang L; Ge YY; Liang YJ; Yong W Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2011 Jun; 23(3):301-6. PubMed ID: 22164498 [TBL] [Abstract][Full Text] [Related]
34. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163 [TBL] [Abstract][Full Text] [Related]
35. Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses. Oh DS; Kim H; Oh JE; Jung HE; Lee YS; Park JH; Lee HK Oncotarget; 2017 Jul; 8(29):47440-47453. PubMed ID: 28537894 [TBL] [Abstract][Full Text] [Related]
36. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721 [TBL] [Abstract][Full Text] [Related]
37. Partial depletion of CD69low-expressing natural regulatory T cells with the anti-CD25 monoclonal antibody PC61. McNeill A; Spittle E; Bäckström BT Scand J Immunol; 2007 Jan; 65(1):63-9. PubMed ID: 17212768 [TBL] [Abstract][Full Text] [Related]
38. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. Correll A; Tuettenberg A; Becker C; Jonuleit H Exp Dermatol; 2010 Aug; 19(8):e213-21. PubMed ID: 20500773 [TBL] [Abstract][Full Text] [Related]
39. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169 [TBL] [Abstract][Full Text] [Related]
40. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Sakaguchi S; Ono M; Setoguchi R; Yagi H; Hori S; Fehervari Z; Shimizu J; Takahashi T; Nomura T Immunol Rev; 2006 Aug; 212():8-27. PubMed ID: 16903903 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]